Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 5/20 | 0.39 |
| ▸ | EGFR | P00533 | 12/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2178613 | 1.00 | AURKA (0.39) | AURKAEGFRCHEK1TNK2JAK2 | |
| SCHEMBL12409636 | 0.91 | AURKA (0.38) | AURKAEGFRCHEK1TNK2JAK2 | |
| SCHEMBL2180924 | 0.91 | AURKA (0.38) | AURKAEGFRCHEK1TNK2JAK2 | |
| SCHEMBL12409666 | 0.91 | EGFR (0.39) | AURKAEGFRCHEK1 | |
| SCHEMBL2178680 | 0.91 | EGFR (0.39) | AURKAEGFRCHEK1 | |
| SCHEMBL12409670 | 0.89 | EGFR (0.40) | AURKAEGFRCHEK1TNK2JAK2 | |
| SCHEMBL2180143 | 0.89 | EGFR (0.40) | AURKAEGFRCHEK1TNK2JAK2 | |
| SCHEMBL2180927 | 0.88 | AURKA (0.37) | AURKAEGFRCHEK1TNK2JAK2 | |
| SCHEMBL2180134 | 0.86 | CHEK1 (0.39) | AURKAEGFRCHEK1TNK2JAK2 | |
| SCHEMBL12409654 | 0.86 | CHEK1 (0.39) | AURKAEGFRCHEK1TNK2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
| WO-2008155016-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | DPYD, TPMT, TYMP | AURKA 2987/4885EGFR 4267/4885CHEK1 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.